Covid-19 roundup: An mR­NA play­er gets a boost out of the lat­est round of an­i­mal da­ta; Phase­Bio pulls the plug on treat­ment tri­al

The big tell for Cure­Vac $CVAC is com­ing up with a loom­ing ear­ly-stage read­out on their mR­NA Covid-19 vac­cine in the clin­ic. But for now they’ll make do with an up­beat as­sess­ment on the pre­clin­i­cal an­i­mal da­ta they used to get in­to the clin­ic.

Re­searchers for the Ger­man biotech say they got the high an­ti­body titers and T cell ac­ti­va­tion they were look­ing for, lin­ing up a ham­ster chal­lenge to demon­strate — in a sim­ple mod­el — that the vac­cine could pro­tect the fur­ry crea­tures. Like the oth­er mR­NA vac­cines, the drug sends in­struc­tions to spur cells to dec­o­rate them­selves with the dis­tinc­tive spike on the virus to elic­it an im­mune re­sponse.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER